{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T03:36:41Z","timestamp":1770435401635,"version":"3.49.0"},"reference-count":23,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2010,10,1]],"date-time":"2010-10-01T00:00:00Z","timestamp":1285891200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nutrition, Metabolism and Cardiovascular Diseases"],"published-print":{"date-parts":[[2010,10]]},"DOI":"10.1016\/j.numecd.2010.07.003","type":"journal-article","created":{"date-parts":[[2010,8,24]],"date-time":"2010-08-24T04:22:45Z","timestamp":1282623765000},"page":"553-557","source":"Crossref","is-referenced-by-count":4,"title":["HDL and LDL as therapeutic targets for cardiovascular disease prevention: The possible role of niacin"],"prefix":"10.1016","volume":"20","author":[{"given":"A.G.","family":"Olsson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.numecd.2010.07.003_bib1","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1001\/jama.231.4.360","article-title":"Clofibrate and niacin in coronary heart disease","volume":"231","author":"CDP Research Group","year":"1975","journal-title":"JAMA"},{"key":"10.1016\/j.numecd.2010.07.003_bib2","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/S0735-1097(86)80293-5","article-title":"Fifteen year mortality in coronary drug project patients: long-term benefit with niacin","volume":"8","author":"Canner","year":"1986","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"10.1016\/j.numecd.2010.07.003_bib3","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1111\/j.0954-6820.1988.tb15891.x","article-title":"Reduction of mortality in the Stockholm ischaemic heart disease secondary prevention study by combined treatment with clofibrate and nicotinic acid","volume":"223","author":"Carlson","year":"1988","journal-title":"Acta Med Scand"},{"issue":"22","key":"10.1016\/j.numecd.2010.07.003_bib4","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1056\/NEJMoa011090","article-title":"Simvastatin and niacin, Antioxidant Vitamins, or the combination for the prevention of coronary disease","volume":"345","author":"Brown","year":"2001","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.numecd.2010.07.003_bib5","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1056\/NEJMoa0907569","article-title":"Extended-Release niacin or ezetimibe and carotid intima-media thickness","volume":"361","author":"Taylor","year":"2009","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.numecd.2010.07.003_bib6","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1016\/j.jacc.2009.06.036","article-title":"Effects of high-dose modified-release nicotinic acid on atherosclerosis and Vascular Function: a randomized, placebo-controlled, magnetic resonance imaging study","volume":"54","author":"Lee","year":"2009","journal-title":"J Am Coll Cardiol"},{"issue":"22","key":"10.1016\/j.numecd.2010.07.003_bib7","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1056\/NEJMe0908838","article-title":"The HALTS trial \u2013 Halting atherosclerosis or Halted Too early?","volume":"361","author":"Blumenthal","year":"2009","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.numecd.2010.07.003_bib8","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1056\/NEJMe0908841","article-title":"Statin therapy with ezetimibe or niacin in high-risk patients","volume":"361","author":"Kastelein","year":"2009","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.numecd.2010.07.003_bib9","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1111\/j.1365-2796.2005.01528.x","article-title":"Nicotinic acid: the broad-spectrum lipid drug. A\u00a050th anniversary review","volume":"258","author":"Carlson","year":"2005","journal-title":"J Intern Med"},{"issue":"12","key":"10.1016\/j.numecd.2010.07.003_bib10","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1001\/jama.297.12.1344","article-title":"Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial","volume":"297","author":"Crouse","year":"2007","journal-title":"JAMA"},{"issue":"13","key":"10.1016\/j.numecd.2010.07.003_bib11","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1056\/NEJMoa0804602","article-title":"Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis","volume":"359","author":"Rossebo","year":"2008","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.numecd.2010.07.003_bib12","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1161\/ATVBAHA.108.173609","article-title":"Correlation between carotid intimal\/medial thickness and atherosclerosis: a point of view from pathology","volume":"30","author":"Finn","year":"2010","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"3","key":"10.1016\/j.numecd.2010.07.003_bib13","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/0021-9150(78)90050-3","article-title":"Coronary Drug Project report on clofibrate and niacin","volume":"30","year":"1978","journal-title":"Atherosclerosis"},{"issue":"12","key":"10.1016\/j.numecd.2010.07.003_bib14","doi-asserted-by":"crossref","first-page":"3634","DOI":"10.1172\/JCI23626","article-title":"GPR109A (PUMA-G\/HM74A) mediates nicotinic acidinduced flushing","volume":"115","author":"Beny\u00f3","year":"2005","journal-title":"J Clin Invest"},{"key":"10.1016\/j.numecd.2010.07.003_bib15","doi-asserted-by":"crossref","unstructured":"Cheng K, Wu T-J, Wu KK, Sturino C, Metters K, Gottesdiener K, et\u00a0al. Antagonism of the prostaglandin D2 receptor 1 suppresses nicotinic acid-induced vasodilation in mice and humans. 2006 April 25, 2006;103(17):6682\u20137.","DOI":"10.1073\/pnas.0601574103"},{"issue":"5","key":"10.1016\/j.numecd.2010.07.003_bib16","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1111\/1523-1747.ep12499963","article-title":"Identification of skin as a major site of prostaglandin D2 release following oral administration of niacin in humans","volume":"98","author":"Morrow","year":"1992","journal-title":"J Invest Dermatol"},{"issue":"4","key":"10.1016\/j.numecd.2010.07.003_bib17","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.ccl.2008.06.007","article-title":"Extended-release niacin\/laropiprant: reducing niacin-induced flushing to better realize the benefit of niacin in improving cardiovascular risk factors","volume":"26","author":"Paolini","year":"2008","journal-title":"Cardiol Clin"},{"issue":"12","key":"10.1016\/j.numecd.2010.07.003_bib18","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1111\/j.1742-1241.2008.01938.x","article-title":"Lipid-modifying efficacy and tolerability of extended-release niacin\/laropiprant in patients with primary hypercholesterolaemia or mixed dyslipidaemia","volume":"62","author":"Maccubbin","year":"2008","journal-title":"Int J Clin Pract"},{"issue":"7","key":"10.1016\/j.numecd.2010.07.003_bib19","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1185\/030079907X199637","article-title":"Validation of a questionnaire to assess niacin-induced cutaneous flushing","volume":"23","author":"Norquist","year":"2007","journal-title":"Curr Med Res Opin"},{"issue":"2","key":"10.1016\/j.numecd.2010.07.003_bib20","first-page":"114","article-title":"Dissociation of the effects of nicotinic acid on vasodilatation and lipolysis by a prostaglandin synthesis inhibitor, indomethacin, in man","volume":"57","author":"Kaijser","year":"1979","journal-title":"Med Biol"},{"key":"10.1016\/j.numecd.2010.07.003_bib21","unstructured":"HPS2-THRIVE: Treatment of High density lipoprotein to Reduce the Incidence of Vascular Events [database on the Internet]. 2008."},{"issue":"5","key":"10.1016\/j.numecd.2010.07.003_bib22","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/j.ahj.2008.07.023","article-title":"Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: vytorin Efficacy International Trial): Comparison of ezetimbe\/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes","volume":"156","author":"Cannon","year":"2008","journal-title":"Am Heart J"},{"issue":"5","key":"10.1016\/j.numecd.2010.07.003_bib23","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.ahj.2010.03.004","article-title":"An update on the improved reduction of outcomes: vytorin efficacy International Trial (IMPROVE-IT) design","volume":"159","author":"Califf","year":"2010","journal-title":"Am Heart J"}],"container-title":["Nutrition, Metabolism and Cardiovascular Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939475310001705?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939475310001705?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T02:56:16Z","timestamp":1559444176000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939475310001705"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,10]]},"references-count":23,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2010,10]]}},"alternative-id":["S0939475310001705"],"URL":"https:\/\/doi.org\/10.1016\/j.numecd.2010.07.003","relation":{},"ISSN":["0939-4753"],"issn-type":[{"value":"0939-4753","type":"print"}],"subject":[],"published":{"date-parts":[[2010,10]]}}}